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108ECG interpretation. Likewise, ECGs acquired in uni-
versity outpatient clinics or university-associated
satellite clinics may be interpreted by a requesting
physician who has little formal training in electro-
cardiography. Unfortunately, there is also no guar-
antee that a cardiologist is competent to read
ECGs because they no longer have to demonstrate
competency in ECG interpretation. In the past, it was
not possible to become a board-certiﬁed cardiologist
if the applicant did not pass the half-day ECG portion
of the examination.
We agree with Dr. Som that “the onus for con-
ﬁrming a speciﬁc ECG should fall on the person who is
the most trained to do so,” which is why we believe
that NPs with special training could be more accurate
in their interpretation than physicians who have
minimal training or interest in electrocardiography.
Competence in ECG reading is easy to test and should
be built into the certiﬁcation process. We agree with
Dr. Som that ECG reading should be integrated with
the clinical problem, and this is the case for NPs who
care for cardiology patients. Just as nurse-managed
care of patients with heart failure has proven supe-
rior to standard care (3–5), we believe it is in the best
interest of our patients to have specially trained NPs
interpret ECGs.*Barbara J. Drew, RN, PhD
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Low-Density Lipoprotein
Cholesterol Level
Is Lower Better?Boekholdt et al. (1), reporting a patient-level meta-
analysis of data from large statin trials, mostly in the
secondary prevention setting, found a clear inverse
relationship between attained low-density lipopro-
tein cholesterol (LDL-C) level and cardiovascular risk
among 38,153 patients allocated to statin therapy.
However, translating these ﬁndings into real-world
clinical practice may not be so straightforward.
The primary prevention cohort study of the J-LIT
(Japan Lipid Intervention Trial) (2), a 6-year, nation-
wide cohort study of 47,294 patients treated
with open-labeled low-dose simvastatin, found a
J-curve between mean achieved LDL-C level and
total mortality; the relative risk of death was signiﬁ-
cantly higher in patients with an LDL-C level <80 mg/
dl or $200 mg/dl compared with the other groups.
Furthermore, in the meta-analysis by Boekholdt
et al. (1), the mean delay in the manifestation of a
clinical cardiovascular event was likely very short
in patients who reached a very low LDL-C level with
respect to other groups. In a secondary prevention
setting, the mean delay of revascularization has been
calculated at 0.09 years (33 days) over 5 years with
a pravastatin-induced reduction in LDL-C level of
43 mg/dl (from 139 to 97 mg/dl) (3). Although it is dif-
ﬁcult to make a similar calculation for the whole
meta-analysis by Boekholdt et al. (1), considering that
revascularization represents an endpoint notoriously
subject to preference that falsely inﬂates beneﬁts, it
seems likely that the delay may be even shorter.
When considering the adverse effects of statin-
induced low LDL-C levels, which are easily dismissed
in randomized trials but not trivial in real life (4,5),
lower LDL-C levels may not be better, especially in
the primary prevention setting. Finally, the authors
of the meta-analysis (1) should provide all-cause
mortality data in relation to achieved LDL-C levels in
both primary and secondary prevention trials.*Luca Mascitelli, MD
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Lipoprotein Cholesterol Level: Is Lower Better?We read with interest the letter by Drs. Mascitelli and
Goldstein commenting on our recent paper (1), in
which we showed that the linear relationship be-
tween levels of low-density lipoprotein cholesterol
and cardiovascular events extends to levels <50 mg/
dl. Our ﬁndings are strongly consistent with the
concept “the lower the better,” but translation of
these ﬁndings into clinical practice is still chal-
lenging. Important reasons for this are the lack of
trial evidence for a lipid target-guided strategy and
the lack of evidence-based effective lipid-lowering
therapies beyond statins. The issues raised by Drs.
Mascitelli and Goldstein are less relevant.
Drs. Mascitelli and Goldstein noted that the pri-
mary prevention J-LIT (Japan Lipid Intervention
Trial) showed an increase in risk of mortality among
patients achieving a total cholesterol (TC) level <160
mg/dl. An important limitation of J-LIT is that it was
not a placebo-controlled trial. If J-LIT had a control
group not on statin therapy, it may well have shown
a similar trend. Of the 28 patients in J-LIT who
achieved a TC level <160 mg/dl and died, 12 died of
malignancy. This association is caused by confound-
ing, that is, (subclinical) malignancies decreasing
cholesterol levels (2,3). Large-scale evidence from
statin trials shows that lowering of cholesterol levels
does not increase the risk of malignancies (4). In
addition, in J-LIT, the statistically signiﬁcant increase
in risk of cardiac events among those achieving a TC
level <160 mg/dl was on the basis of just 4 events,
and the nonsigniﬁcant increased risk of stroke was
also on the basis of just 4 events. In our meta-
analysis, 351 fatal cardiovascular events occurredamong those achieving a TC level <160 mg/dl, which
makes our results statistically more reliable.
Drs. Mascitelli and Goldstein also pointed out that
revascularization is a subjective outcome measure.
Although the decision to perform elective revascu-
larization may indeed be subjective, associations
with risk factors tend to be in line with “hard” car-
diovascular outcomes. Still, for 7 of the 8 trials,
elective revascularizations were not included in the
pooled outcomes of our meta-analysis; in the TNT
(Treatment to New Targets) trial, elective revascu-
larization for stable angina and unplanned revascu-
larization for unstable angina could not be separated,
and therefore both were included in the pooled
outcomes (5).
Finally, Drs. Mascitelli and Goldstein stressed the
fact that myopathy is not a trivial adverse effect of
statins in clinical practice. We agree with this remark,
as discussed extensively in our paper. Unfortunately,
data on adverse effects and all-cause mortality
were not obtained from the individual trials for the
purpose of this meta-analysis.
In conclusion, the results of our meta-analysis are
largely consistent with the concept “the lower the
better” and warrant new trials to formally test this
hypothesis.S. Matthijs Boekholdt, MD, PhD
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